Preeclampsia Diagnostics Market to grow at a CAGR of 3.8% from 2022-2031, reaching US$ 2.3 Billion: TMR Study

The global market for 𝐩𝐫𝐞𝐞𝐜𝐥𝐚𝐦𝐩𝐬𝐢𝐚 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 reached a valuation of US$ 1.5 billion in 2021 and is forecasted to grow at a Compound Annual Growth Rate (CAGR) of 3.8%, ultimately reaching US$ 2.3 billion by the conclusion of 2031.

Preeclampsia, a condition specific to pregnancy, manifests as a multisystem disorder characterized by hypertension (>140/90 mm Hg) coupled with the new onset of proteinuria (>300 mg in 24 hours) after 20 weeks of gestation. The increasing prevalence of preeclampsia worldwide is expected to drive advancements in the preeclampsia diagnostics market in the forthcoming years.

𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32423&utm_source=OpenPR&utm_campaign=MansiR

With preeclampsia impacting approximately 2% to 8% of pregnancies globally, heightened awareness regarding this condition and its diagnostic protocols among expectant mothers is likely to fuel the expansion of the preeclampsia diagnostics market in the foreseeable future. Market players are directing their efforts towards research and development endeavors aimed at introducing technologically advanced products, thereby positioning themselves to reap revenue benefits.

Preeclampsia is a pregnancy complication characterized by elevated blood pressure (systolic ≥140 mm Hg or diastolic ≥90 mm Hg) and proteinuria after the 20th week of pregnancy. Pregnancy-induced hypertension, without proteinuria, is diagnosed if only hypertension develops. Chronic hypertension, present before the 20th week, is another hypertensive issue during pregnancy. Preeclampsia often manifests near the end of pregnancy with minimal symptoms. In severe cases, complications like eclampsia, cerebral hemorrhage, pulmonary edema, kidney failure, liver damage, and blood clotting abnormalities can occur, affecting about 1 in 100 women with preeclampsia.

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤:

In 2021, North America held a leading market share of 35% globally, with a projected CAGR of over 3.6% during the forecast period. The region's growth is fueled by increasing awareness of preeclampsia diagnosis among pregnant women, prompting organizations and major players to invest more in research and development for advanced detection products, thus creating lucrative opportunities.

Asia Pacific emerged as the fastest-growing market in 2021, expected to grow at a CAGR of 4.4% during the forecast period. This growth is attributed to rising preeclampsia prevalence, burgeoning populations in India and China, improved availability and awareness of preeclampsia tests, and enhancements in healthcare infrastructure. Moreover, increased awareness of preeclampsia and its treatment is anticipated to further drive market growth in the region.

𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:

Abbott Laboratories, ACON Laboratories, Inc., ARKRAY, Inc., Bio-Rad Laboratories, Inc., Cardinal Health, Danaher Corporation (Beckman Coulter, Inc.), Diabetomics, Inc., DIRUI Industrial Co., Ltd., F. Hoffmann-La Roche Ltd., Metabolomic Diagnostics Ltd., Sera Prognostics, and Siemens Healthineers AG.

𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

Test Type

Blood Test
Urine Test
Others

Product & Services

Instruments
Reagents & Consumables
Services

End-user

Hospitals
Diagnostic Centers
Others

𝐆𝐞𝐭 𝐓𝐡𝐢𝐬 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭, 𝐈𝐧𝐬𝐭𝐚𝐧𝐭𝐥𝐲:
https://www.transparencymarketresearch.com/checkout.php?rep_id=32423<ype=S&utm_source=OpenPR&utm_campaign=MansiR

𝐊𝐞𝐲 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬:

In July 2022, PerkinElmer, Inc. announced that a placental growth factor (PlGF) measurement using its DELFIA Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA Xpress sFlt-1 kit (CE-IVD), have been included in updated diagnostic guidance issued by the United Kingdom's National Institute for Health and Care Excellence (NICE) to help diagnose suspected preterm preeclampsia

In February 2020, Shuwen Biotech Co. Ltd., a China-based leader in developing innovative diagnostics products announced that PerkinElmer, Inc. would distribute Shuwen's breakthrough diagnostic test for preeclampsia in over 100 countries around the globe, accounting for over 120 million pregnancies annually

In May 2019, FIGO released new guidelines to combat preeclampsia, and calls for all women to receive first-trimester screening

In May 2018, Metabolomic Diagnostics secured €2 Mn in European Union funding under the Horizon 2020 SME Instrument, an initiative to accelerate growth in small- and medium-sized companies. The company is all set to support the commercialization of the preterm preeclampsia test, PrePsia.

In September 2017, Siemens Healthineers announced that it received the CE Mark certification. The company also declared the commercial availability of its versatile Atellica Solution in Europe, the U.S., South America, and Asia. This developed for the upcoming challenges in the testing procedures in the labs.

𝐑𝐞𝐠𝐢𝐨𝐧𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝:

North America(USA, Canada and Mexico)
Europe(UK, Germany, France and the Rest of Europe)
Asia Pacific(China, Japan, India, and the Rest of the Asia Pacific region)
South America(Brazil, Argentina and the Rest of South America)
Middle East and Africa(GCC and Rest of the Middle East and Africa)

𝐌𝐚𝐫𝐤𝐞𝐭 𝐓𝐫𝐞𝐧𝐝𝐬:

Adoption of non-invasive diagnostic techniques such as biomarker-based tests and imaging modalities.
Integration of artificial intelligence (AI) and machine learning algorithms for accurate prediction and early detection of preeclampsia.
Development of point-of-care testing devices for convenient and rapid diagnosis.

𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐭𝐮𝐝𝐲 𝐏𝐨𝐢𝐧𝐭𝐬:

Assessment of market dynamics, including drivers, challenges, and trends.
Analysis of market segmentation based on service type, sourcing type, application, industry vertical, and region.
Evaluation of regional market trends and opportunities.
Examination of competitive landscape, including key players, market share analysis, and recent developments.

𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐓𝐌𝐑:

𝐓𝐫𝐚𝐜𝐡𝐞𝐨𝐬𝐭𝐨𝐦𝐲 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2023/04/04/2641254/0/en/Tracheostomy-Devices-Market-Size-to-Cross-USD-291-3-Mn-Revenue-by-2031-Due-to-the-Rise-in-Demand-for-Homecare-Services-TMR-Study.html

𝐏𝐞𝐧𝐢𝐜𝐢𝐥𝐥𝐢𝐧 𝐆 𝐀𝐜𝐲𝐥𝐚𝐬𝐞 𝐌𝐚𝐫𝐤𝐞𝐭- https://www.globenewswire.com/news-release/2023/04/04/2641179/0/en/Penicillin-G-Acylase-Market-to-Surpass-USD-1-1-Bn-Revenue-by-2031-Exclusive-Research-by-TMR.html

𝐀𝐛𝐨𝐮𝐭 𝐓𝐫𝐚𝐧𝐬𝐩𝐚𝐫𝐞𝐧𝐜𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com   
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube

This release was published on openPR.